Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6297]

FDA approves daratumumab and hyaluronidase-fihj for high-risk smouldering multiple myeloma

FDA approves daratumumab and hyaluronidase-fihj for high-risk smouldering multiple myeloma

New cancer drug shows exceptional tumour-fighting potential

New cancer drug shows exceptional tumour-fighting potential

RNA modification m⁶A emerges as key player in cancer development and therapy

RNA modification m⁶A emerges as key player in cancer development and therapy

Abnormal transport signal on mutant UBTF gene drives high-risk acute myeloid leukaemia

Abnormal transport signal on mutant UBTF gene drives high-risk acute myeloid leukaemia

Advanced breast cancer patients living longer thanks to improvements in treatment and care

Advanced breast cancer patients living longer thanks to improvements in treatment and care

Targeting immune checkpoint therapy: the role of manganese in tumour immunotherapy

Targeting immune checkpoint therapy: the role of manganese in tumour immunotherapy

Early clinical trial tests immune-boosting therapy before prostate cancer surgery

Early clinical trial tests immune-boosting therapy before prostate cancer surgery

Tumour-on-a-chip offers insight into cancer-fighting cells in immunotherapy

Tumour-on-a-chip offers insight into cancer-fighting cells in immunotherapy

$FDA approves revumenib for relapsed or refractory acute myeloid leukaemia with a susceptible NPM1 mutation$

FDA approves revumenib for relapsed or refractory acute myeloid leukaemia with a susceptible NPM1 mutation

Drug that stops tumour blood supply could have role in paediatric bone cancer

Drug that stops tumour blood supply could have role in paediatric bone cancer

More from ecancer